Editorially Independent content supported with advertising by Genentech
Priya Sharma Vakharia, MD
Show Description +
How do you weigh the decision to switch to a new anti-VEGF agent in a wet AMD patient who has responded well—but not optimally—to a given treatment and has hit a treatment interval ceiling? Priya Sharma Vakharia, MD, reviews a real-world case from her clinic and hears how Joseph M. Coney, MD, and Yasha S. Modi, MD, would approach this patient.
Posted: 1/15/2024
Priya Sharma Vakharia, MD
How do you weigh the decision to switch to a new anti-VEGF agent in a wet AMD patient who has responded well—but not optimally—to a given treatment and has hit a treatment interval ceiling? Priya Sharma Vakharia, MD, reviews a real-world case from her clinic and hears how Joseph M. Coney, MD, and Yasha S. Modi, MD, would approach this patient.
Posted: 1/15/2024
Please log in to leave a comment.